Summary
Gain comprehensive insight about the multidisciplinary team’s role in guiding patients with resectable gastroesophageal junction cancer through the full course of care, including surgery, neoadjuvant, and adjuvant treatment. Faculty will discuss how to establish clear patient expectations, review recent trial data and surgical outcomes (including perspectives on overall survival results from CheckMate 577 and Matterhorn), and operating after neoadjuvant immunotherapy and targeted therapies through evidence-based best practices.
Supported by AstraZeneca
Moderator
Stephanie G. Worrell, MD
University of Arizona
Tucson, AZ
Speakers
Katherine D. Gray, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Matthew Strickland, MD
Massachusetts General Hospital
Boston, MA
